p38α Mitogen-activated Protein Kinase Sensitizes Cells to Apoptosis Induced by Different Stimuli
Mice, Knockout
STAT3 Transcription Factor
0303 health sciences
MAP Kinase Signaling System
Apoptosis
Fibroblasts
Embryo, Mammalian
DNA-Binding Proteins
Enzyme Activation
Mitogen-Activated Protein Kinase 14
Mice
03 medical and health sciences
Proto-Oncogene Proteins c-bcl-2
Proto-Oncogene Proteins
Trans-Activators
Animals
Myocytes, Cardiac
Mitogen-Activated Protein Kinases
Phosphorylation
Cells, Cultured
Signal Transduction
bcl-2-Associated X Protein
DOI:
10.1091/mbc.e03-08-0592
Publication Date:
2003-11-18T01:23:24Z
AUTHORS (8)
ABSTRACT
p38α mitogen-activated protein (MAP) kinase is a broadly expressed signaling molecule that participates in the regulation of cellular responses to stress as well as in the control of proliferation and survival of many cell types. We have used cell lines derived from p38α knockout mice to study the role of this signaling pathway in the regulation of apoptosis. Here, we show that cardiomyocytes and fibroblasts lacking p38α are more resistant to apoptosis induced by different stimuli. The reduced apoptosis of p38α-deficient cells correlates with decreased expression of the mitochondrial proapoptotic protein Bax and the apoptosis-inducing receptor Fas/CD-95. Cells lacking p38α also have increased extracellular signal-regulated kinase (ERKs) MAP kinase activity, and the up-regulation of this survival pathway seems to be at least partially responsible for the reduced levels of apoptosis in the absence of p38α. Phosphorylation of the transcription factor STAT3 on Ser-727, mediated by the extracellular signal-regulated kinase MAP kinase pathway, may contribute to the decrease in both Bax and Fas expression in p38α-/- cells. Thus, p38α seems to sensitize cells to apoptosis via both up-regulation of proapoptotic proteins and down-regulation of survival pathways.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (71)
CITATIONS (196)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....